{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.4","upperLimit":"24.7","value":"15"},{"groupId":"OG001","lowerLimit":"7.0","upperLimit":"13.8","value":"13"},{"groupId":"OG002","lowerLimit":"5.0","upperLimit":"10.7","value":"8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"83"},{"groupId":"OG002","value":"83"}],"units":"Participants"}],"description":"PFS, assessed based on IMWG criteria per blind IRC assessment, is defined as the time from date of randomization to date of first documented disease progression or death (regardless of cause of death).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 20 mg panobinostat TIW, 2 weeks on/1 week off in combination with subcutaneous bortezomib and oral dexamethasone.","id":"OG000","title":"Arm A - Panobinostat (20 mg, TIW)"},{"description":"Participants received 20 mg panobinostat BIW, 2 weeks on/1 week off in combination with subcutaneous bortezomib and oral dexamethasone.","id":"OG001","title":"Arm B - Panobinostat (20 mg, BIW)"},{"description":"Participants received 10 mg panobinostat TIW, 2 weeks on/1 week off in combination with subcutaneous bortezomib and oral dexamethasone.","id":"OG002","title":"Arm C - Panobinostat (10 mg, TIW)"}],"paramType":"MEDIAN","populationDescription":"Full analysis set (FAS): all participants to whom study treatment was assigned by randomization.","reportingStatus":"POSTED","timeFrame":"Up to 5.2 years","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}